Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02616562 · ClinicalTrials.gov registry record · Phase 2
Investigating Efficacy and Safety of Once-weekly NNC0195-0092 Treatment Compared to Daily Growth Hormone Treatment (Norditropin® FlexPro®) in Growth Hormone Treatment naïve Pre-pubertal Children With Growth Hormone Deficiency
A Phase 2 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 2
- Development phase
- 76
- Enrollment target
NCT02616562 is a Phase 2 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 76 participants.
The verdict
NCT02616562, a Phase 2 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 76 participants
- Enrollment target
Study Summary
This trial is conducted globally. The aim of the trial is to investigate efficacy and safety of once-weekly NNC0195-0092 treatment compared to daily growth hormone treatment (Norditropin® FlexPro®) in growth hormone treatment naïve pre-pubertal children with growth hormone deficiency. The main trial period will consist of 26 weeks of treatment, followed by a 26 week extension period.
Interventions
- DRUG somapacitan
- DRUG Norditropin® FlexPro® pen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2016-03-31 |
| Est. Completion | 2024-09-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02616562
The ClinicalTrials.gov registry entry for NCT02616562 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which somapacitan is the first listed.
NCT02616562 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02616562 about?
NCT02616562 is a clinical study titled "Investigating Efficacy and Safety of Once-weekly NNC0195-0092 Treatment Compared to Daily Growth Hormone Treatment (Norditropin® FlexPro®) in Growth Hormone Treatment naïve Pre-pubertal Children With Growth Hormone Deficiency". This trial is conducted globally. The aim of the trial is to investigate efficacy and safety of once-weekly NNC0195-0092 treatment compared to daily growth hormone treatment (Norditropin® FlexPro®) in growth hormone treatment naïve pre-pubertal children with growth hormone deficiency. The main tria...
What is the current status of trial NCT02616562?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 76 participants. The study started on 2016-03-31. Estimated completion is 2024-09-26.
What interventions are being tested in trial NCT02616562?
The interventions under investigation include: somapacitan (DRUG), Norditropin® FlexPro® pen (DRUG).
Who is sponsoring clinical trial NCT02616562?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.